Wade Clapp

1.1k total citations
12 papers, 659 citations indexed

About

Wade Clapp is a scholar working on Neurology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Wade Clapp has authored 12 papers receiving a total of 659 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Neurology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Wade Clapp's work include Neurofibromatosis and Schwannoma Cases (7 papers), Neuroblastoma Research and Treatments (4 papers) and Sarcoma Diagnosis and Treatment (3 papers). Wade Clapp is often cited by papers focused on Neurofibromatosis and Schwannoma Cases (7 papers), Neuroblastoma Research and Treatments (4 papers) and Sarcoma Diagnosis and Treatment (3 papers). Wade Clapp collaborates with scholars based in United States, United Kingdom and Belgium. Wade Clapp's co-authors include Mark D’Esposito, Tyler M. Seibert, Jesse Rissman, Jeffrey W. Cooney, A Rutman, Adam Gazzaley, Armelle Luscan, Nicolás Ortonne, Éric Pasmant and Hildegard Kehrer‐Sawatzki and has published in prestigious journals such as Nature, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Wade Clapp

12 papers receiving 652 citations

Peers

Wade Clapp

NEURO

PRM

ONCOL

Alessandro Salvalaggio Italy

Katsuzo Kunishio Japan

J P Fryns Belgium

Veronica Saletti Italy

Yuil Kim South Korea

Mie‐Jef Descheemaeker Belgium

Tena Rosser United States

Allen D. Berry United States

Carmen Orellana Spain

Ivan S. Kotchetkov United States

Alessandro Salvalaggio Italy

Wade Clapp

113 ×0.5

227 ×1.1

223 ×1.2

NEURO

70 ×0.5

PRM

72 ×1.4

ONCOL

Citations per year, relative to Wade Clapp Wade Clapp (= 1×) peers Alessandro Salvalaggio

Countries citing papers authored by Wade Clapp

Since Specialization

Citations

This map shows the geographic impact of Wade Clapp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wade Clapp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wade Clapp more than expected).

Fields of papers citing papers by Wade Clapp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wade Clapp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wade Clapp. The network helps show where Wade Clapp may publish in the future.

Co-authorship network of co-authors of Wade Clapp

This figure shows the co-authorship network connecting the top 25 collaborators of Wade Clapp. A scholar is included among the top collaborators of Wade Clapp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wade Clapp. Wade Clapp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Mueller, Sabine, Alyssa Reddy, Eva Dombi, et al.. (2020). NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM. Neuro-Oncology. 22(Supplement_3). iii420–iii421. 13 indexed citations

Shih, Chie‐Schin, Jaishri Blakely, Wade Clapp, et al.. (2018). NFM-01. NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY. Neuro-Oncology. 20(suppl_2). i142–i142. 2 indexed citations

Blakeley, Jaishri O., Annette Bakker, Anne Barker, et al.. (2017). The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis. American Journal of Medical Genetics Part A. 173(6). 1714–1721. 4 indexed citations

Plotkin, Scott R., James H. Tonsgard, Nicole J. Ullrich, et al.. (2017). RARE-19. MULTICENTER, PHASE 2 STUDY OF BEVACIZUMAB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. Neuro-Oncology. 19(suppl_6). vi215–vi215. 1 indexed citations

Bradford, Diana, Patricia Whitcomb, Eva Dombi, et al.. (2016). Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).. Journal of Clinical Oncology. 34(15_suppl). TPS2596–TPS2596. 1 indexed citations

Raedt, Thomas De, Eline Beert, Éric Pasmant, et al.. (2014). PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 514(7521). 247–251. 329 indexed citations

Raedt, Thomas De, Eline Beert, Éric Pasmant, et al.. (2014). Abstract LB-79: PRC2 loss amplifies Ras-driven transcription and sensitizes cancers to bromodomain inhibitor-based combination therapies. Cancer Research. 74(19_Supplement). LB–79. 1 indexed citations

Nalepa, Grzegorz, Jill S. Barnholtz‐Sloan, Dilip Dey, et al.. (2013). The tumor suppressor CDKN3 controls mitosis. The Journal of Cell Biology. 201(7). 997–1012. 72 indexed citations

Barnholtz‐Sloan, Jill S., Dilip Dey, Ying He, et al.. (2013). The tumor suppressor CDKN3 controls mitosis. The Journal of Cell Biology. 202(4). 717–717. 8 indexed citations

10.

Robertson, Kent A., Daniel C. Bowers, Fu‐Chi Yang, et al.. (2011). Phase II pilot study of imatinib mesylate in neurofibromatosis (NF1) patients with plexiform neurofibromas.. Journal of Clinical Oncology. 29(15_suppl). 10030–10030. 1 indexed citations

11.

Gazzaley, Adam, Jesse Rissman, Jeffrey W. Cooney, et al.. (2007). Functional Interactions between Prefrontal and Visual Association Cortex Contribute to Top-Down Modulation of Visual Processing. Cerebral Cortex. 17(suppl 1). i125–i135. 221 indexed citations

12.

Yu, Xijie, et al.. (2006). Neurofibromatosis Type 1 Gene Haploinsufficiency Reduces AP-1 Gene Expression without Abrogating the Anabolic Effect of Parathyroid Hormone. Calcified Tissue International. 78(3). 162–170. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact